Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis

Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir

(2018) Jennifer A Fulcher et al.   CLINICAL INFECTIOUS DISEASES

Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel

(2018) Huldrych F Günthard et al.   CLINICAL INFECTIOUS DISEASES

Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada

(2018) Hezhao Ji et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

HIV drug resistance against strand transfer integrase inhibitors

(2017) Kaitlin Anstett et al.   Retrovirology

Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance

(2017) Bluma G. Brenner et al.   VIRUS RESEARCH

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

(2017) Isabelle Malet et al.   mBio

Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013

(2016) A. Zoufaly et al.   INFECTION

Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study

(2016) Alexandra U. Scherrer et al.   JOURNAL OF INFECTIOUS DISEASES

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study

(2016) Phairote Teeranaipong et al.   PLoS One

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

(2015) Thibault Mesplède et al.   Viruses-Basel

Performance of HIV-1 Drug Resistance Testing at Low-Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naive Individuals

(2014) A. Gonzalez-Serna et al.   CLINICAL INFECTIOUS DISEASES

Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) Cohort

(2014) Sophie Patterson et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

(2014) Alessandro Cozzi-Lepri et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance

(2014) I. Hardy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Resistance to HIV Integrase Strand Transfer Inhibitors Among Clinical Specimens in the United States, 2009–2012

(2013) Christopher B. Hurt et al.   CLINICAL INFECTIOUS DISEASES

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

(2013) Thibault Mesplède et al.   Retrovirology

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

(2012) Calvin J. Cohen et al.   AIDS

Automating HIV Drug Resistance Genotyping with RECall, a Freely Accessible Sequence Analysis Tool

(2012) Conan K. Woods et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Spillover adherence effects of fixed-dose combination HIV therapy

(2012) Teresa Kauf et al.   Patient Preference and Adherence

HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications

(2011) Jose-Luis Blanco et al.   JOURNAL OF INFECTIOUS DISEASES

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

(2011) Myron S. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study

(2010) Jose M Gatell et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

(2009) S. Fransen et al.   JOURNAL OF VIROLOGY

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET